AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity

Nature Structural and Molecular Biology

Volumn 16, Issue 7, 2009, Pages 769-776

  Wang, Meng ^a   Yang, Zizhen ^a   Rada, Cristina ^a   Neuberger, Michael S ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; DNA DEAMINASE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; BACTERIAL PAPILLATION ASSAY; CANCER IMMUNOLOGY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA LIBRARY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; GENE MUTATION; GENOMIC INSTABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SPLEEN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY DIVERSITY; BIOLOGICAL ASSAY; CYTIDINE DEAMINASE; HUMANS; IMMUNE SYSTEM; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; NUCLEOSIDE DEAMINASES; SEQUENCE HOMOLOGY, AMINO ACID; TAKIFUGU; TRANSLOCATION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 67650330317     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1623     Document Type: Article

References (50)

1. Alt, F.W. & Honjo, T. (eds.). AID for Immunoglobulin Diversity. Advances in Immunology Vol. 94 (Elsevier, Amsterdam;, 2007).
2. Di Noia, J.M. & Neuberger, M.S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
3. Chiu, Y.L. & Greene, W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26, 317-353 (2008).
4. Haché, G., Mansky, L.M. & Harris, R.S. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 8, 148-157 (2006).
5. de Yébenes, V.G. & Ramiro, A.R. Activation-induced deaminase: light and dark sides. Trends Mol. Med. 12, 432-439 (2006).
6. Okazaki, I.M. et al. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197, 1173-1181 (2003).
7. Ramiro, A.R. et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440, 105-109 (2006).
8. Robbiani, D.F. et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135, 1028-1038 (2008).
9. Nghiem, Y., Cabrera, M., Cupples, C.G. & Miller, J.H. The mutY gene: a locus in Escherichia coli that generates G·C→T·A transversions. Proc. Natl. Acad. Sci. USA 85, 2709-2713 (1988).
10. Ruiz, S.M., Létourneau, S. & Cupples, C.G. Isolation and characterization of an Escherichia coli strain with a high frequency of C-to-T mutations at 5-methylcytosines. J. Bacteriol. 175, 4985-4989 (1993).
11. Cupples, C.G. & Miller, J.H. A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc. Natl. Acad. Sci. USA 86, 5345-5349 (1989).
12. Conticello, S.G., Langlois, M.A. & Neuberger, M.S. Insights into DNA deaminases. Nat. Struct. Mol. Biol. 14, 7-9 (2007).
13. Chen, K.M. et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119 (2008).
14. Holden, L.G. et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124 (2008).
15. Larijani, M. et al. AID associates with single-stranded DNA with high affinity and a long complex half-life in a sequence-independent manner. Mol. Cell. Biol. 27, 20-30 (2007).
16. Conticello, S.G., Thomas, C.J., Petersen-Mahrt, S.K. & Neuberger, M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22, 367-377 (2005).
17. Barreto, V., Reina-San-Martin, B., Ramiro, A.R., McBride, K.M. & Nussenzweig, M.C. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol. Cell 12, 501-508 (2003).
18. Ta, V.T. et al. AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat. Immunol. 4, 843-848 (2003).
19. de Yébenes, V.G. et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J. Exp. Med. 205, 2199-2206 (2008).
20. Dorsett, Y. et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 28, 630-638 (2008).
21. McBride, K.M. et al. Regulation of class switch recombination and somatic mutation by AID phosphorylation. J. Exp. Med. 205, 2585-2594 (2008).
22. Pauklin, S., Sernandez, I.V., Bachmann, G., Ramiro, A.R. & Petersen-Mahrt, S.K. Estrogen directly activates AID transcription and function. J. Exp. Med. 206, 99-111 (2009).
23. Sernández, I.V., de Yébenes, V.G., Dorsett, Y. & Ramiro, A.R. Haploinsufficiency of activation-induced deaminase for antibody diversification and chromosome translocations both in vitro and in vivo. PLoS One 3, e3927 (2008).
24. Takizawa, M. et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp. Med. 205, 1949-1957 (2008).
25. Teng, G. et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28, 621-629 (2008).
26. Arakawa, H., Saribasak, H. & Buerstedde, J.M. Activation-induced cytidine deaminase initiates immunoglobulin gene conversion and hypermutation by a common intermediate. PLoS Biol. 2, e179 (2004).
27. Conticello, S.G. et al. Interaction between antibody- diversification enzyme AID and spliceosome-associated factor CTNNBL1. Mol. Cell 31, 474-484 (2008).
28. Janz, S., Müller, J., Shaughnessy, J. & Potter, M. Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 90, 7361-7365 (1993).
29. LaRue, R.S. et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83, 494-497 (2009).
30. LaRue, R.S. et al. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9, 104 (2008).
31. Chaudhuri, J., Khuong, C. & Alt, F.W. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 430, 992-998 (2004).
32. Basu, U. et al. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature 438, 508-511 (2005).
33. Clarke, S.H. et al. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161, 687-704 (1985).
34. Berek, C. & Milstein, C. Mutation drift and repertoire shift in the maturation of the immune response. Immunol. Rev. 96, 23-41 (1987).
35. Celada, F. & Seiden, P.E. Affinity maturation and hypermutation in a simulation of the humoral immune response. Eur. J. Immunol. 26, 1350-1358 (1996).
36. Kepler, T.B. & Perelson, A.S. Somatic hypermutation in B cells: an optimal control treatment. J. Theor. Biol. 164, 37-64 (1993).
37. Kepler, T.B. & Perelson, A.S. Modeling and optimization of populations subject to time-dependent mutation. Proc. Natl. Acad. Sci. USA 92, 8219-8223 (1995).
38. Kleinstein, S.H., Louzoun, Y. & Shlomchik, M.J. Estimating hypermutation rates from clonal tree data. J. Immunol. 171, 4639-4649 (2003).
39. Arakawa, H. et al. Protein evolution by hypermutation and selection in the B cell line DT40. Nucleic Acids Res. 36, e1 (2008).
40. Cumbers, S.J. et al. Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines. Nat. Biotechnol. 20, 1129-1134 (2002).
41. Wang, L., Jackson, W.C., Steinbach, P.A. & Tsien, R.Y. Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc. Natl. Acad. Sci. USA 101, 16745-16749 (2004).
42. Bransteitter, R., Pham, P., Calabrese, P. & Goodman, M.F. Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase. J. Biol. Chem. 279, 51612-51621 (2004).
43. Bennett, R.P. et al. APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic. Biochem. Biophys. Res. Commun. 350, 214-219 (2006).
44. Bennett, R.P., Presnyak, V., Wedekind, J.E. & Smith, H.C. Nuclear exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J. Biol. Chem. 283, 7320-7327 (2008).
45. Stenglein, M.D., Matsuo, H. & Harris, R.S. Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 82, 9591-9599 (2008).
46. Chen, H. et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16, 480-485 (2006).
47. Petersen-Mahrt, S.K., Harris, R.S. & Neuberger, M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418, 99-104 (2002).
48. Guzman, L.M., Belin, D., Carson, M.J. & Beckwith, J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 177, 4121-4130 (1995).
49. Di Noia, J.M. et al. Dependence of antibody gene diversification on uracil excision. J. Exp. Med. 204, 3209-3219 (2007).
50. Sale, J.E., Calandrini, D.M., Takata, M., Takeda, S. & Neuberger, M.S. Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. Nature 412, 921-926 (2001).